4 August 2020 in European Journal of Haematology
VDValeria Estefania Delgado‐Pinos
Valeria Estefania Delgado‐Pinos
+7
30 July 2020 in Journal of Oncology Pharmacy Practice
Introduction: Methotrexate intoxication following high-dose methotrexate-induced acute kidney injury is a life-threatening complication. Glucarpidase can quickly reduce extracellular methotrexate to safe levels, but the effectiveness and safety of its use in different episodes of nephrotoxicity remain an unknown area. Case Report: A 30-year-old male diagnosed with acute lymphoblastic T-cell lymphoma received methotrexate 5 g/m2 intravenous (IV) as part of the first consolidation cycle. On Consolidation 3, he restarted methotrexate at a dose of 3 g/m2 IV showing slow methotrexate elimination, associated myelosuppression, and hepatic toxicity. Glucarpidase was administered (total dose of 2000 International Units (IU)). No adverse events were observed, and his renal function returned to normal. One hundred and six days later, he was diagnosed with leptomeningeal and cerebellar relapse and treatment with methotrexate 3,5 g/m2 IV day 1 and cytosine arabinoside (Ara-C) 2 g/m2 IV twice per day days 1, 3, and 5 was started. At 36 h from methotrexate infusion, serum creatinine increased up to 1.89 mg/dL and methotrexate concentration was 100 µmol/L. Management and Outcome: Ara-C was suspended, and a second administration of glucarpidase (2000 IU) was dispensed. No adverse events were noticed, methotrexate levels decreased and renal function progressively improved, recovering completely three weeks later. Discussion: The effectiveness and safety of the use of glucarpidase in different episodes of nephrotoxicity remain an unknown area, and the rate and consequences of antiglucarpidase antibody formation remain poorly understood. This case report is, to our knowledge, the first case of a second administration of glucarpidase in a different cycle of high-dose methotrexate in an adult patient.
3 February 2021 in Journal of Clinical Apheresis
IRIsabel Regalado‐Artamendi
Isabel Regalado‐Artamendi
RMReyes María Martín‐Rojas
+1
8 September 2026 in Frontiers in Medicine
Introduction: Current recommendations for hematologic response (HemR) assessment in monoclonal gammopathies of renal significance (MGRS) are based on the monoclonal immunoglobulin (MIg) component responsible for renal damage. Light-chain (LC) amyloidosis criteria are recommended when renal lesions are due to LC, whereas multiple myeloma (MM) criteria are proposed when due to an intact monoclonal immunoglobulin. However, the nephrotoxic MIg is frequently not measurable either by the International Myeloma Working Group (IMWG) or the International Society of Amyloidosis (ISA) criteria. Methods: In the study shown below, we retrospectively analyzed an original multi-center series of 45 MGRS patients. Results: Thirty-two MGRS-non-amyloidosis (MGRS-NA) and 13 MGRS-amyloidosis (MGRS-A) patients were included. Twelve (37.5%) and 15 (47%) MGRS-NA patients had measurable disease by either the IMWG or ISA criteria, respectively. According to the IMWG criteria, 5% of MGRS-NA patients with intact MIg renal deposits and 80% with exclusively LC deposits had measurable disease, as determined by serum electrophoresis or sFLC assay, respectively. Based on the ISA criteria, 35 and 80% of MGRS-NA patients with MIg and LC renal deposits, respectively, had measurable disease. Discussion: Our findings reveal the limitations of the current proposed HemR assessment in MGRS-NA patients and explore potential alternatives to ease clinical practice and guideline development.